HOTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hoth Therapeutics Inc (HOTH) is not a strong buy for a beginner, long-term investor at this moment. While the company has promising developments in its pipeline, the lack of significant financial performance improvements, technical signals, and trading trends suggests that waiting for more concrete progress or a better entry point would be prudent.
The MACD is slightly positive but contracting, RSI is neutral at 49.275, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 1.029, with support at 0.975 and resistance at 1.083. Overall, there is no strong technical signal for a buy.
Hoth Therapeutics has integrated OpenAI's API into its HT-KIT development workflow, achieving significant tumor volume reduction and preparing for IND submission and Phase 1 clinical trials. HT-KIT has shown over 80% suppression of KIT mRNA and protein in models, which is promising for rare cancer treatment.
The company has no revenue and continues to operate at a net loss (-$4.1M in Q3 2025). EPS has declined by 6.25% YoY, and there are no significant trading trends from hedge funds or insiders.
In Q3 2025, revenue remained at $0 with no growth. Net income improved by 84.2% YoY but is still negative at -$4.1M. EPS dropped to -0.3, down 6.25% YoY. Gross margin remains at 0%. Overall, the financials indicate a struggling company with no revenue generation.
No analyst rating or price target data is available for HOTH.
